IP Library Granted Patent US 9,399,635
Granted Patent B2
US 9,399,635 · App. 14/110,188 · Granted Jul 26, 2016

Pyrazole derivative

Inventors: Hachiro Sugimoto (Kyoto, JP); Michiaki Okuda (Kyoto, JP); Takashi Takahashi (Tokyo, JP); Ichiro Hijikuro (Tokyo, JP); Hidetaka Suzuki (Tokyo, JP); Shinichi Nakayama (Kyoto, JP)
Assignee: GREEN TECH CO., LTD.
C07D401/14C07D209/12C07D401/12C07D403/06C07D403/10C07D403/14C07D405/12C07D405/14C07D409/12C07D409/14C07D417/12C07D417/14C07H15/203C07H15/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,399,635
App. No.
14/110,188
Granted
Jul 26, 2016
Kind
B2
Abstract

Provided is a novel therapeutic means for Alzheimer's disease. In particular, provided is a compound represented by the following general formula (I): [wherein Ar 1 represents 2-methoxy-4-(2-pyridylmethoxy)phenyl etc. and Ar 2 represents a 1H-indol-6-yl group etc.] or a salt thereof.

Claims (20)

1. A compound represented by the following general formula (I):

[wherein R represents hydrogen, a chain or cyclic hydrocarbon group optionally having a substituent, or a heterocyclic group optionally having a substituent; and

Ar 1 represents a phenyl group having a C 1-3 alkyloxy group substituted with a heterocycloalkyl group optionally having a substituent, a phenyl group having a C 1-3 alkyloxy group substituted with a cycloalkyl group optionally having a substituent, a phenyl group having a C 1-3 alkyloxy group substituted with a heteroaryl group optionally having a substituent, a phenyl group having a C 1-3 alkyloxy group substituted with an aryl group optionally having a substituent, a phenyl group having a C 1-3 alkyloxy group substituted with a dialkylamino group optionally having a substituent, a phenyl group having a C 1-3 alkyloxy group substituted with an alkyloxy group optionally having a substituent, or a phenyl group having a C 1-3 alkyloxy group substituted with an alkyl group optionally having a substituent and Ar 2 , which is identical to or different from Ar 1 and each represents a homocyclic or heterocyclic group optionally having a substituent;

or a salt thereof.

2. The compound or a salt thereof according to claim 1 , wherein R in the general formula (I) is hydrogen.

3. The compound or a salt thereof according to claim 1 , wherein Ar 1 in the general formula (I) is a phenyl group having a tetrahydrofuran-3-ylmethoxy group, a tetrahydrofuran-2-ylmethoxy group, a 2-(piperidin-1-yl)ethoxy group, a 2-(4-methylpiperazino)ethoxy group, a 2-(4-benzylpiperazino)ethoxy group, a 2-morpholinoethoxy group, a 2-pyrrolidinoethoxy group, a β-D-glucopyranosyloxy group, a 2-[4-(tert-butoxycarbonyl)piperazin-1-yl]ethoxy group, a 2-[4-(methylsulfonyl)piperazin-1-yl]ethoxy group, or a 2-[ 4 -(2-hydroxyethyl)piperazin-1-yl]ethoxy group.

4. The compound or a salt thereof according to claim 1 , wherein Ar 1 in the general formula (I) is a 2-methoxy-4-(tetrahydrofuran-3-ylmethoxy)phenyl group, a 2-methoxy-4-(tetrahydrofuran-2-ylmethoxy)phenyl group, a 2-methoxy-4-[2-(piperidin-1-yl)ethoxy]phenyl group, a 2-methoxy-4-[2-(4-methylpiperazino)ethoxy]phenyl group, a 2-methoxy-4-(2-morpholinoethoxy)phenyl group, a 4-(β-D-glucopyranosyl)oxy-2-methoxyphenyl group, a 4-(tetrahydrofuran-3-ylmethoxy)phenyl group, a 4-(tetrahydrofuran-2-ylmethoxy)phenyl group, a 3-methoxy-4-(tetrahydrofuran-3-ylmethoxy)phenyl group, a 3-methoxy-4-(tetrahydrofuran-2-ylmethoxy)phenyl group, a 2-[2-(4-benzylpiperazino)ethoxy]-4-methoxyphenyl group, a 4-diethylamino-2-(2-morpholinoethoxy)phenyl group, a 4-dimethylamino-2-(2-morpholinoethoxy)phenyl group, a 4-diethylamino-2-(2-morpholinoethoxy)phenyl group, a 4-diethylamino-2-(2-pyrrolidinoethoxy)phenyl group, or a 4-diethylamino-2[2-(piperidin-1-yl)ethoxy]phenyl group.

5. The compound or a salt thereof according to claim 1 , wherein Ar 1 in the general formula (I) is a phenyl group having a pyridin-2ylmethoxy group, a pyridin-3-ylmethoxy group, a pyridin-4-ylmethoxy group, or a 1-pyrrolylmethoxy group.

6. The compound or a salt thereof according to claim 1 , wherein Ar 1 in the general formula (I) is a 4-(pyridin-2-ylmethoxy)phenyl group, a 2-methoxy-4-(pyridin-2-ylmethoxy)phenyl group, a 2-[2-(piperidin-1-yl)ethoxy]-4-(pyridin-2-ylmethoxy)phenyl group, a 2-(2-morpholinoethoxy)-4-(pyridin-2-ylmethoxy)phenyl group, a 2-(2-pyrrolidinoethoxy)-4-(pyridin-2-ylmethoxy)phenyl group, a 2-[2-(4-methylpiperazino)ethoxy]-4-(pyridin-2-ylmethoxy)phenyl group, a 3-methoxy-4-(pyridin-2-ylmethoxy)phenyl group, a 2-hydroxy-4-(pyridin-2-ylmethoxy)phenyl group, a 3-(pyridin-2-ylmethoxy)phenyl group, a 2-methoxy-3-(pyridin-2-ylmethoxy)phenyl group, a 4-methoxy-3-(pyridin-2-ylmethoxy)phenyl group, a 3-methoxy-5-(pyridin-2-ylmethoxy)phenyl group, a 2-methoxy-5-(pyridin-2-ylmethoxy)phenyl group, a 2-(pyridin-2-ylmethoxy)phenyl group, a 4-methoxy-2-(pyridin-2-ylmethoxy)phenyl group, a 5-methoxy-2-(pyridin-2-ylmethoxy)phenyl group, a 2-nitro-5-(pyridin-3-ylmethoxy)phenyl group, a 4-diethylamino-2-(pyridin-3-ylmethoxy)phenyl group, or a 2-methoxy-2-(1-pyrrolylmethoxy)phenyl group.

7. The compound or a salt thereof according to claim 1 , wherein Ar 2 in the general formula (I) is a bicyclic homocyclic or heterocyclic group optionally having a substituent.

8. The compound or a salt thereof according to claim 1 , wherein Ar 2 in the general formula (I) is a bicyclic heterocyclic group optionally having a substituent.

9. The compound or a salt thereof according to claim 8 , wherein Ar 2 in the general formula (I) is an indol-2-yl group, an indol-3-yl group, an indol-4-yl group, an indol-5-yl group, an indol-6-yl group, an indol-7-yl group, a benzotriazol-5-yl group, a benzimidazol-5-yl group, a quinoxalin-6-yl group, a benzofuran-2-yl group, a benzothiophen-2-yl group, a 1H-indazol-5-yl group, a 7-azaindol-3-yl group, a quinolin-2-yl group, a quinolin-5-yl group, a quinolin-8-yl group, a 1,4-benzodioxan-6-yl group, a 1,3-benzodioxol-5-yl group, a chromon-3-yl group, a coumarin-6-yl group, a 7-methoxycoumarin-4-yl group, or a 4-methoxycoumarin-6-yl group.

10. The compound or a salt thereof according to claim 8 , wherein Ar 2 in the general formula (I) is a bicyclic heterocyclic group having a methyl group, an ethyl group, a benzyl group, an acetyl group, a benzoyl group, a tert-butoxycarbonyl group, a methylsulfonyl group, a p-toluenesulfonyl group, a hydroxy group, or a nitro group.

11. The compound or a salt thereof according to claim 8 , wherein Ar 2 in the general formula (I) is a 1-methylindol-6-yl group, a 1-methylindol-2-yl group, a 1-methylindol-3-yl group, a 1-ethylindol-6-yl group, a 1-benzylindol-3-yl group, a 1-benzylindol-6-yl group, a 1-acetylindol-3-yl group, a 1-acetylindol-6-yl group, a 1-benzoylindol-3-yl group, a 1-tert-butoxycarbonylindol-5-yl group, a 1-methylsulfonylindol-3-yl group, a 1-methylsulfonylindol-6-yl group, a 1-p-toluenesulfonylindol-3-yl group, a 1-p-toluenesulfonylindol-6-yl group, a 4-hydroxyindol-3-yl group, or a 4-nitroindol-3-yl group.

12. A tau aggregation inhibitor comprising the compound or a salt thereof according to claim 1 as an active ingredient.

13. A β-secretase inhibitor comprising the compound or a salt thereof according to claim 1 as an active ingredient.

14. An amyloid β-protein aggregation inhibitor comprising the compound or a salt thereof according to claim 1 as an active ingredient.

15. A pharmaceutical composition comprising the compound or a salt thereof according to claim 1 as an active ingredient.

16. A method for treating a disease in which tau, β-secretase, or amyloid β-protein is involved, wherein the disease is Alzheimer's disease, comprising a step of administering an effective amount of pharmaceutical composition according to claim 15 .

17. An oral or parenteral preparation comprising the compound or a salt thereof according to claim 1 and one or more pharmacologically acceptable carriers.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2014
From: SUGIMOTO, HACHIRO
To: GREEN TECH CO., LTD.
Reel/Frame 034021/0054 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE ASSIGNOR NAME PREVIOUSLY RECORDED ON REEL 033410 FRAME 0667. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 8, 2014
From: PHARMA EIGHT CO. LTD.
To: SUGIMOTO, HACHIRO
Reel/Frame 033501/0017 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2014
From: MUNAKATA, KEI-ICHI
To: HACHIRO SUGIMOTO
Reel/Frame 033410/0667 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2013
From: SUGIMOTO, HACHIRO; OKUDA, MICHIAKI; TAKAHASHI, TAKASHI; HIJIKURO, ICHIRO; SUZUKI, HIDETAKA; NAKAYAMA, SHINICHI
To: PHARMA EIGHT CO., LTD.
Reel/Frame 031791/0139 →
Priority Claims (1)
JP 2011-087040 · Apr 11, 2011 · national
Continuity (1)
Related Publication 20140088029A1 · Mar 27, 2014